The prevalence of community-acquired meticillin-resistant Staphylococcus aureus (CA-MRSA) strains has become a serious problem worldwide. The aim of this study was to investigate the annual transitions of MRSA strains with the CA-MRSA feature, which were identified as SCCmec type IV or V, in a hospital setting in Japan. Between 2005 and 2012, MRSA strains were collected from a tertiary-care hospital in Tokyo, Japan, and SCCmec typing, detection of the virulence factors and antimicrobial susceptibility testing were conducted. The rate of detection of type II SCCmec, which is found mainly in healthcare-associated MRSA, significantly decreased from 90.0 (2005)(2006) [2005][2006] to 2.1 % (2011-2012) (P,0.01). The resistance rates of cefotaxime, levofloxacin, clarithromycin and minocycline decreased every year. The resistance rates of these antimicrobial agents for the SCCmec type IV or V strains were significantly lower than those for the SCCmec type I or II strains (P,0.01, respectively). Therefore, these results suggest that the annual transitions of the virulence factors and antibiograms in MRSA are closely related to the increase of SCCmec type IV/V strains.
INTRODUCTION
Meticillin-resistant Staphylococcus aureus (MRSA) is one of the major pathogens in hospital and community settings. In Japan, the isolation rate of MRSA in hospital settings is higher than that of other countries. Thus, the appropriate use of antimicrobial agents is strongly recommended (Diekema et al., 2001; Niki et al., 2011) . gene complexes (International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements, 2009; Li et al., 2011; Shore et al., 2011) . SCCmec types I-III are mainly found in HA-MRSA, whilst types IV and V are mainly found in CA-MRSA (Boye et al., 2007) .
The prevalence of CA-MRSA strains in hospital settings is a serious worldwide problem (DeLeo et al., 2010; Chuang & Huang, 2013) , although little is known about the distribution of CA-MRSA strains in Japanese hospitals. Furthermore, HA-MRSA strains with CA-MRSA features have tended to increase worldwide (Campanile et al., 2009; Nichol et al., 2011) . Additionally, large-scale surveillance has shown that the antimicrobial resistance of both HA-MRSA and CA-MRSA strains has decreased in recent years (Campanile et al., 2009; Landrum et al., 2012) . Many reports presenting results of MRSA isolated from several hospitals over a short period have been published; however, studies on the long-term surveillance for MRSA are extremely limited (Campanile et al., 2009; Nichol et al., 2011; Takata et al., 2012) . As such, long-term surveillance targeting a single hospital would be more detailed and show an accurate transition of MRSA, because it is possible to more consistently investigate the same conditions. Therefore, the aim of this study was to investigate the annual transitions of MRSA strains with the CA-MRSA feature, which have been classified into SCCmec type IV or V, in a hospital setting in Japan. We investigated the annual transitions of the SCCmec types, rates of possession of virulence factors and antimicrobial susceptibilities for MRSA strains isolated from a tertiary-care hospital in Tokyo, Japan, between 2005 and 2012. (Nakaminami et al., 2008) .
METHODS
Growth condition and bacterial identification. All strains were cultured on tryptone soy agar (Oxoid) under aerobic conditions at 35 uC for 24 h. All collected isolates were confirmed as S. aureus by growth on mannitol salt agar (Oxoid), Gram staining and coagulase production (PS Latex; Eiken Chemical) (Nakaminami et al., 2008) . Furthermore, MRSA strains were identified by coagulase testing, growth on Mueller-Hinton agar (Oxoid) containing 6 mg oxacillin ml 21 (Sigma-Aldrich) and 4% NaCl, and PCR-based detection of the mecA gene (Noguchi et al., 2006) . PCR amplification. PCR assays for the detection of mecA, the toxic shock syndrome toxin-1 gene tst and the PVL gene pvl were performed as described previously (Nakaminami et al., 2008) . PCR was performed in the following cycles: for mecA, 25 cycles (30 s denaturation at 95 uC, 30 s annealing at 58 uC and 30 s extension at 72 uC) and for tst and pvl, 25 cycles (30 s denaturation at 95 uC, 30 s annealing at 55 uC and 60 s extension at 72 uC). SCCmec typing was performed according to the method of Boye et al. (2007) , and the strains not identified as SCCmec types I-V were classified as non-typable (Boye et al., 2007) . PCR for SCCmec typing was performed in the following cycles: 30 cycles (30 s denaturation at 94 uC, 30 s annealing at 55 uC and 60 s extension at 72 uC). The PCR samples were prepared in 100 ml sterile water containing a single MRSA colony, which was isolated from a streaking plate (Noguchi et al., 2006) .
Antimicrobial susceptibility testing. MICs were determined by an agar doubling-dilution method, according to the Clinical and Laboratory Standards Institute guidelines (CLSI, 2009). The following antimicrobial agents were used: ampicillin (Wako), oxacillin (SigmaAldrich), cefotaxime (Wako), levofloxacin (Wako), sitafloxacin (Daiichi Sankyo), clarithromycin (Wako), gentamicin (Wako), arbekacin (Meiji Seika Pharma), minocycline (Sigma-Aldrich), vancomycin (Sigma-Aldrich), teicoplanin (Sanofi) and linezolid (Pfizer). The breakpoints of these antimicrobial agents were determined using the Clinical and Laboratory Standards Institute interpretation criteria and unknown breakpoints were defined in this study (Nakaminami et al., 2014) .
Statistical analysis. The annual transition of the MRSA strains was compared every 2 years. Differences in the rates of antimicrobial resistance, SCCmec types and toxin genes were tested by a x 2 test using JMP software (SAS Institute). Pv0.05 was considered statistically significant. 
RESULTS

SCCmec typing
After confirmation in our laboratory, a total of 2339 isolates were identified as being MRSA (Table 1) . SCCmec types of these isolates are shown in (Table 3) .
Detection of virulence factors
When the detection of toxin genes was conducted, tst and pvl genes were found in 1501 (64.2%) and 17 (0.7%) MRSA strains, respectively ( A. Ito and others type I, II, IV, V and non-typable, respectively. However, 17 pvl-positive strains were divided into 11.8, 82.4 and 5.9% SCCmec type II, IV and non-typable, respectively. Interestingly, two strains carrying both tst and pvl genes were detected and classified into SCCmec type IV.
Antimicrobial susceptibility
The antimicrobial susceptibilities of all MRSA strains were determined (Table 5) . As no significant difference was found in the MIC distributions, no notable change was observed in the MIC 50 and MIC 90 values of the antimicrobial agents, excluding minocycline. Although no notable transition of the resistance rates of penicillins was observed, the resistance rate of cefotaxime was significantly decreased every year (Pv0.05). The resistance rates of fluoroquinolones showed a tendency to decrease. In addition, the resistance rate of clarithromycin was significantly decreased every year (Pv0.01). No notable transition of the resistance rate of gentamicin was observed. The resistance rate of minocycline was significantly decreased every year (Pv0.01). All strains were susceptible to vancomycin, teicoplanin and linezolid. Sixteen isolates were resistant (MIC > 8 mg ml 21 ) to arbekacin.
Antimicrobial susceptibilities in SCCmec type I/II and IV/V strains
The antimicrobial susceptibilities for the strains carrying SCCmec types I/II and IV/V were compared (Table 6 ). The MIC 50 s of b-lactams, fluoroquinolones, clarithromycin, gentamicin and minocycline for the strains carrying SCCmec type IV/V were lower than those for the strains carrying SCCmec type I/II. For ampicillin, sitafloxacin, arbekacin, minocycline and teicoplanin, MIC 90 s for the strains carrying SCCmec type IV/V were lower than those for the strains carrying SCCmec type I/II. Although no significant differences were found in the resistance rates of penicillins, the resistance rates of cefotaxime, levofloxacin, sitafloxacin, clarithromycin and minocycline for the strains carrying SCCmec type IV/V were significantly lower than those for the strains carrying SCCmec type I/II (Pv0.01, respectively). In contrast, the resistance rate of gentamicin for the strains carrying SCCmec type IV/V was higher than that for the strains carrying SCCmec type I/II. No notable differences of the susceptibility to anti-MRSA agents were observed.
DISCUSSION
Long-term surveillance of MRSA strains isolated from the hospital setting provides a way to predict the annual transitions of virulence factors and antibiograms. The information will contribute to the effective control of hospital infections and the treatment of infections caused by MRSA.
In this study, MRSA strains of SCCmec type II, which are mainly found in HA-MRSA, were significantly decreased, whilst those of SCCmec type IV, which are mainly found in CA-MRSA, were significantly increased, as also seen in other countries (Nichol et al., 2011) . Many strains carrying SCCmec type I/II were isolated from patients undergoing long-term hospitalization, such as in the Department of Surgery. In contrast, the strains of SCCmec type IV/V were frequently isolated from patients of the Departments of Dermatology and Paediatrics, which contain many outpatients. Therefore, the MRSA strains with CA-MRSA features isolated in the hospital setting were presumed to be transmitted from the community setting via outpatients. It will be necessary to note the trend of CA-MRSA in the hospital setting in the future.
With regard to the annual transition of virulence factors, the rate of detection of the tst gene was found to significantly decrease ever year and 89.1% of the strains carrying tst were SCCmec type II, indicating that the trend of decreasing numbers of strains carrying tst is presumed to be related to a decrease in the strains carrying SCCmec type II. However, the ratio of the pvl-positive strains was found to increase every year and the pvl gene was mainly found in the strains of SCCmec type IV in this study. In the US and Europe, the pvl gene has been known to be mainly distributed in CA-MRSA strains (Zetola et al., 2005) . However, it was reported that PVL-positive MRSA infections have been rare in Japan since 2000 (Isobe et al., 2012) . Our results indicate CA-MRSA carrying pvl may be gradually increasing in Japan.
With regard to antimicrobial susceptibility testing, whilst no notable differences of MIC distribution were observed, the resistance rates of antimicrobial agents, excluding ampicillin, oxacillin, gentamicin, and arbekacin, showed a decreasing trend. These results suggest that the increase in the number of strains exhibiting an under-breakpoint of the MIC led to a decrease in the resistance rates of the antimicrobial agents. Additionally, the resistance rates of cefotaxime, levofloxacin, sitafloxacin, clarithromycin and minocycline for the strains carrying SCCmec type IV/V were significantly lower than those for the strains carrying SCCmec type I/II. Generally, HA-MRSA strains exhibit high-level and multidrug resistance against non-b-lactam antimicrobial agents as compared with CA-MRSA strains.
As the strains with SCCmec type I/II accounted for *90% of all strains in [2005] [2006] , it can be presumed that the annual transitions of antimicrobial susceptibility to cefotaxime, levofloxacin, clarithromycin and minocycline were affected by the decreased prevalence of the type I/II cassette in later years. In contrast, the resistance rate of gentamicin for the strains carrying SCCmec type IV/V was higher than that for the strains carrying SCCmec type I/II. In this study, 16 arbekacin-resistant strains were found. The details of the arbekacin-resistant strains are still unknown. Further study is necessary to understand these arbekacin-resistant strains.
Thus, our results show that strains with CA-MRSA features invaded the hospital setting, contributing to the change of antimicrobial agent susceptibility and the prevalence of toxin genes in MRSA isolated from the hospital. In the future, it can be presumed that the strains with CA-MRSA features, which indicate susceptibility to antimicrobial agents and high toxicity, will increase in hospitals and infection control may be considered in the community.
